China Sky One Medical (CSKI) Subsidiary Receives Production Approval from China's State FDA for 4 New Drugs

December 23, 2008 8:33 AM EST

China Sky One Medical, Inc. (Nasdaq: CSKI) announced today that its subsidiary, Heilongjiang Tianlong Pharmaceutical, Inc., successfully obtained production approval from the State FDA in China for four of its newly developed drugs.

• Dithranol ointment is intended to treat different types of psoriasis, such as plaque psoriasis, guttate psoriasis and hypertrophy psoriasis;
  
• Antipruritic tincture is intended to soothe itchy skin and reduce inflammation; it can also be used for infection and bruises;
  
• Antiasthma cream is intended to treat cough, asthma and chronic bronchitis; and
  
• Levofloxacin Lactate injection is used to treat moderate to severe respiratory system, urinary system, and digestive system infections, as well as soft skin tissue infections. It can also treat septicemia, urethritis, and cervicitis.

China Sky One Medical, Inc., through its subsidiaries, engages in the development, manufacture, marketing, and sale of over-the-counter nutritional supplements and herb based pharmaceutical and medicinal products primarily in the People's Republic of China.

Create E-mail AlertRelated Categories

Corporate News
FDA

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?